Trial Profile
A Study to evaluate the autoantibodies in immune complexes as a predictor of response to belimumab in patients with Systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2020
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism